Search Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapyHematologic NeoplasmsProtocol groupAggressive LymphomasIndolent LymphomasTransplantationDiseaseChronic Lymphocytic Leukemia / Small Lymphocytic LymphomaMantle Cell LymphomaNHL, B-Cell Type, Diffuse Large CellNHL, B-Cell Type, Follicular Grade I-IIIaNHL, B-Cell Type, Follicular grade IIIbNHL, B-Cell Type, IndolentNHL, B-Cell Type, Lymphoplasmocytic / Waldenström's diseaseNHL, B-Cell Type, Marginal Zone LymphomaSubgroupCD20+unfitICD10C82.-C82.7C82.9C83.0C83.1C83.3C88.0-C91.1-MeSHLymphoma, FollicularLymphoma, Mantle-CellWaldenstrom MacroglobulinemiaSequenceBORT1,3, Waldenström, C1 (PID2343) -|- C2 (PID2342) -|- C3,4 (PID2344) -|- C5 (PID2342).BORT1,6/RITU375, Waldenström, C1 (PID1235) -|- C2+3 (PID1266) -|- C4 (PID1235) -|- C5+6 (PID1266)CARF20/RITU375/DEXA20, Waldenström, C1 (PID2586) -|- C2-6 (PID2587) -|- C7-14 (PID2588)iNNOVATE: IBRU420/RITU375, Waldenström (PID1255) -|- IBRU420/RITU375, Maint. (PID1265)IXAC4/DEXA20, Waldenström, C1-2 (PID2025) -|- C3 (PID2026) -|- C4-8 (PID2027)IXAZ4/RITU1400/DEXA20, Waldenström (PID2025) -|- (PID2026) -|- (PID2027) -|- (PID310)VNTC(400/800), Waldenström, C1 (PID2003) -|- VNTC800, C2+ (PID2004)ChemotherapyChemo-substanceBendamustineBortezomibCarfilzomibCarmustineCyclophosphamideCytarabineDexamethasoneDoxorubicinEtoposideFludarabineIbrutinibIdelalisibIxazomibMelphalanPrednisoloneRituximabVenetoclaxVincristineZanubrutinibChemo-substanceBendamustineBortezomibCarfilzomibCarmustineCyclophosphamideCytarabineDexamethasoneDoxorubicinEtoposideFludarabineIbrutinibIdelalisibIxazomibMelphalanPrednisoloneRituximabVenetoclaxVincristineZanubrutinibChemo-substanceBendamustineBortezomibCarfilzomibCarmustineCyclophosphamideCytarabineDexamethasoneDoxorubicinEtoposideFludarabineIbrutinibIdelalisibIxazomibMelphalanPrednisoloneRituximabVenetoclaxVincristineZanubrutinibChemo-substanceBendamustineBortezomibCarfilzomibCarmustineCyclophosphamideCytarabineDexamethasoneDoxorubicinEtoposideFludarabineIbrutinibIdelalisibIxazomibMelphalanPrednisoloneRituximabVenetoclaxVincristineZanubrutinibNo. Substances123456 RadiotherapySupportive therapySupportive substanceAciclovirAllopurinolAmphotericin BBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDimetindenFilgrastimFosaprepitantGranisetronMesnaParacetamolPegfilgrastimPrednisoloneSupportive substanceAciclovirAllopurinolAmphotericin BBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDimetindenFilgrastimFosaprepitantGranisetronMesnaParacetamolPegfilgrastimPrednisoloneSupportive substanceAciclovirAllopurinolAmphotericin BBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDimetindenFilgrastimFosaprepitantGranisetronMesnaParacetamolPegfilgrastimPrednisoloneSupportive substanceAciclovirAllopurinolAmphotericin BBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDimetindenFilgrastimFosaprepitantGranisetronMesnaParacetamolPegfilgrastimPrednisoloneNo. Substances12345679Protocol classificationTherapy classificationalternativecurrent standardindividual (author)IntensityLow doseStandard doseTherapy indicationFirst lineRelapse therapySecond lineseveral possibleTherapy phaseInductionMaintenanceSalvageTherapy intentioncurativedisease controlpalliativeRisksAllergic ReactionAnemia Hb below 8g/dlAnemia Hb below 10g/dlArthalgiaAstheniaAtrial FibrillationBleedingCardiotoxicityConstipationDiarrheaDyspneaEdemaEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)FatigueFebrile NeutropeniaHeadacheHematuriaHyperbilirubinemiaHyperglycemiaHypertensionHypotensionIncrease AminotransferasesIncrease in lipaseInfectionsInfusion ReactionLeukopeniaMyalgiasNauseaNeuropathyNeutropeniaPainPneumoniaPyrexiaRashThrombocytopenia below 50 000/µlUpper Respiratory Tract Infection only studiesPublicationAuthorBuske CCastillo JJDimopolous MDimopoulos MDimopoulos MAGavriatopoulou MGhobrial IMGopal AKHerold MKersten MKirschey SRobinson KSRummel MJSekiguchi NTam CSTedeschi ATreon SPTreon SP DiseaseFoll. L. °I-IIIa, kleines lymphozyt. L., Marginalzonenl., lymphoplasmoyt. L., Drittlinie bei Rituximab- u Alkylanz-RefraktäritätFoll. Lymphom Grad 1-2, MCL, lymphoplasmozytisches Lymphom, Therapieindikation, Erstlinie ECOG 0-2fortgeschrittener oder rezidivierter Morbus Waldenström, ECOG 0-2fortgeschrittenes follikuläres Lymphom, Mantelzelllymphom und Morbus Waldenström, Stadium III-IV, Erstlinie, ECOG 0-2MCL, follikuläres (Grad 1und 2), lymphoplasmozytisches, Marginalzonen-, kleines lymphozytisches Lymphom, Std. III u IV, ErstlinieMCL, follikuläres, lymphoplasmozytisches, kleines lymphozytisches u Marginalzonen-Lymphom, 2.-4.-LinieMorbus WaldenströmMorbus Waldenström, Alter über 65Morbus Waldenström, CD20+, ErstlinieMorbus Waldenström, Erstlinie oder Rezidivtherapie, ECOG: 0-2Morbus Waldenström, symptomatisch, Erst-oder ZweitlinieMorbus Waldenström, symptomatisch, ErstlinieMorbus Waldenström, Zweitlinie, rezidiv oder refraktär, ECOG 0-1Morbus Waldenström symptomatisch, Erstlinierezidivierte aggressive B-NHL, 18-65 Jahre, ECOG 0-2Waldenström´s Macroglobulinämie, MYD88 L265P pos., mindestens 1 Vortherapie, ECOG 0-2Waldenström´s Macroglobulinämie, MYD88 L265P pos., rezidiviert, therapierefraktär, oder ungeeignet für eine ChemotherapieWaldenström´s Macroglobulinämie, Zweitlinie, ECOG 0-2OriginBing Center for Waldenström´s Macrglobulinemia, Dana Faber-Institute, Boston, MA, USADana-Farber Cancer Institute, Boston, MADana-Farber Cancer Institute and Harvard Medical School, Boston, USADepartment of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, iNNOVATE StudyDepartment of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, iNNOVATE trialDepartment of Clinical Therapeutics, University of Athens School of Medicine, Athens, GreeceDepartment of Haematology, Oncology and Pneumology, University Medical School of the Johannes Gutenberg University MainzDepartment of Hematology, University of Amsterdam, HOVON124/ ECWM-R2 StudyDepartment of Internal Medicine III, University ofMunich, German Low-Grade Lymphoma Study GroupDepartment of Medicine, Division of Medical Oncology, University of Washington School of Medicine, USADepartments of Clinical Therapeutics, Internal Medicine, and the Second Department of Propedeutic Medicine, University of Athens School of MedicineDivision of Hematology, Ospedale Niguarda Ca´Granda, Milano, ItalyHelios Klinikum, Hämatologie/Onkologie, Erfurt, Deutschland, Studie OSHO# 19Hematology Division, National Hospital Organization Disaster Medical Center, Tachikawa, TokyoNational and Kapodistrian University of Athens, Athens, GreecePeter MacCallum Cancer Centre, Melbourne, VIC, Australia, BGB-3111-302 (ASPEN trial)QE II Helath Sciences Centre, Halifax, Nova Scotia, CanadaStudy Group indolent Lymphomas (StiL)Protocols in Revision 28 protocols foundProtocols under revision.Bortezomib 1,3, Waldenström's disease, cycle 1 (PID2343)Bortezomib 1.6 / Rituximab 375 - Bortezomib 1.6 Waldenström's disease, cycle 2+3+5+6 (PID1266)Bortezomib 1.6 / Rituximab 375 / Dexamethasone 40, Waldenström's disease, cycle 2,5 (PID2342)Bortezomib 1.6 / Rituximab 375, Waldenström's disease, cycle 1+4 (PID1235)Bortezomib 1.6, Waldenström's disease, cycle 3-4 (PID2344)Carfilzomib 20 / Rituximab 375 / Dexamethasone 20, Waldenström, cycle 1 (PID2586)Carfilzomib 36 / Rituximab 375 / Dexamethasone 20, Waldenström, cycle 2-6 (PID2587)Carfilzomib 36 / Rituximab 375 / Dexamethasone 20, Waldenström, cycle 7-14 (PID2588)Dexamethasone 20 / Rituximab 375 / Cyclophosphamide 100, Waldenström's disease (PID52)Ibrutinib 420 / Rituximab 375, Waldenström's disease (PID1255)Ibrutinib 420 / Rituximab 375, Waldenström's disease, maintenance (PID1265)Ibrutinib 420, Waldenström's disease (PID585)Idelalisib 150, indolent B-non-Hodgkin Lymphoma (PID308)Ixazomib 4 / Dexamethasone 20, Waldenström's disease, cycle 1-2 (PID2025)Ixazomib 4 / Rituximab 1400 / Dexamethasone 20, Waldenström's disease, cycle 4-8 (PID2027)Ixazomib 4 / Rituximab 375 / Dexamethasone 20, Waldenström's disease, cycle 3 (PID2026)R-BOP - Rituximab 375 / Bendamustine 60 / Vincristine 2 / Prednisolone 100, indolent B non-Hodgkin Lymphoma and Mantle Cell Lymphoma (PID297)R-CHOP - Rituximab 375 / Cyclophosphamide 750 / Doxorubicin 50 / Vincristine 2 / Prednisolone, 100 Waldenström's disease (PID676)R-COP - Rituximab 375 / Cyclophosphamide 400 / Vincristine 2 / Prednisolone 100, indolent B non-Hodgkin Lymphoma and Mantle Cell Lymphoma (PID298)R-DexaBEAM - Rituximab 375 / Dexamethasone 8 / Carmustine 60 / Etoposide 75 / Cytarabine 100 / Melphalan 20, B-Non-Hodgkin Lymphoma (PID1006)R-FC - Rituximab 375 / Fludarabine 25 / Cyclophosphamide 250, Waldenström's disease (PID674)R-miniCHOP - Rituximab 375 / Cyclophosphamide 375 / Doxorubicin 25 / Vincristine 0.7 / Prednisolone 60, Waldenström's disease (PID673)Rituximab 375 / Bendamustine 90, indolent B-non-Hodgkin Lymphoma and Mantle Cell Lymphoma, first-line (PID271)Rituximab 375 / Bendamustine 90, indolent B-non-Hodgkin Lymphoma and Mantle Cell Lymphoma, second line (PID270)Rituximab 375, Waldenström's disease (PID677)Venetoclax (400/800), Waldenström's disease, cycle 1 (PID2003)Venetoclax 800, Waldenström's disease, cycle 2+ (PID2004)Zanubrutinib 160, Waldenström's disease (PID1918)